Preventing epilepsy using adenosine therapies
Therapies for epilepsy prevention - focus on adenosine
['FUNDING_R01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-10897311
This study is looking at how certain approved medications might help prevent epilepsy by changing how the brain handles a chemical called adenosine, and it's being tested in lab animals to see if it can stop the condition from getting worse.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-10897311 on ClinicalTrials.gov |
What this research studies
This research focuses on developing therapies to prevent epilepsy and its progression by targeting adenosine metabolism. The approach involves testing existing FDA-approved drugs in rodent models to see if they can interfere with the processes that lead to epilepsy. Specifically, the study will explore the use of an A2A receptor blocker and a GLT-1 activator to address the dysregulation of glutamate and glial activation that contribute to epilepsy. By understanding and manipulating these mechanisms, the research aims to find effective interventions for epilepsy prevention.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of brain injury or other conditions that may predispose them to developing epilepsy.
Not a fit: Patients who already have established epilepsy or those without any risk factors for developing epilepsy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent the onset of epilepsy, significantly improving the quality of life for patients at risk.
How similar studies have performed: Other research has shown promise in using similar approaches to target adenosine pathways for neurological conditions, indicating potential for success in this area.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOISON, DETLEV — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: BOISON, DETLEV
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.